Journal of the Egyptian National Cancer Institute · 2025
A case-control study investigating the impact of gradient pressure therapy on chemotherapy-induced peripheral neuropathy symptoms and daily activities in paclitaxel-treated patients.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guo Dongxue, Zhao Fangfei, Hu JiWei, Zhang JingHua, Du Aijun, Zhou Lizhi
Аннотация
PURPOSE: Paclitaxel chemotherapy is known to induce peripheral neuropathy, significantly impacting patients' daily activities. Effective interventions to alleviate these symptoms are crucial for improving patient quality of life. The objective was to investigate the effects of gradient pressure therapy on symptoms of paclitaxel-induced peripheral neuropathy and daily activities.
METHODS: Eighty patients with breast cancer receiving a 125-mg/m2 paclitaxel chemotherapy regimen at a class III hospital in Tangshan from October 2022 to October 2023 were randomly divided into a control group (n = 40) and an intervention group (n = 40). The control group received routine treatment and health guidance, whereas the intervention group received additional II-level hand and foot gradient pressure therapy. Chemotherapy-induced peripheral neuropathy (CIPN) symptoms and activities of daily living (ADL) impact scores were compared after the second, fourth, and sixth chemotherapy cycles and at the 3-month follow-up.
RESULTS: No significant differences were found in CIPN symptoms and ADL impact scores between the groups after the second chemotherapy cycle (P > 0.05). However, after the fourth cycle, the intervention group showed significant improvements in nine items: hand numbness, foot numbness, discomfort in fingers/hands or toes/feet, walking, exercise, sleep, sexual activity, chores, and enjoyment of life (P < 0.05). At the sixth cycle and at the 3-month follow-up, additional improvements were noted in cold sensitivity and total scores (P < 0.05).
CONCLUSION: Gradient pressure therapy effectively reduces symptoms of paclitaxel-induced peripheral neuropathy, improving patients' daily activities. This intervention is recommended for clinical promotion and application.
METHODS: Eighty patients with breast cancer receiving a 125-mg/m2 paclitaxel chemotherapy regimen at a class III hospital in Tangshan from October 2022 to October 2023 were randomly divided into a control group (n = 40) and an intervention group (n = 40). The control group received routine treatment and health guidance, whereas the intervention group received additional II-level hand and foot gradient pressure therapy. Chemotherapy-induced peripheral neuropathy (CIPN) symptoms and activities of daily living (ADL) impact scores were compared after the second, fourth, and sixth chemotherapy cycles and at the 3-month follow-up.
RESULTS: No significant differences were found in CIPN symptoms and ADL impact scores between the groups after the second chemotherapy cycle (P > 0.05). However, after the fourth cycle, the intervention group showed significant improvements in nine items: hand numbness, foot numbness, discomfort in fingers/hands or toes/feet, walking, exercise, sleep, sexual activity, chores, and enjoyment of life (P < 0.05). At the sixth cycle and at the 3-month follow-up, additional improvements were noted in cold sensitivity and total scores (P < 0.05).
CONCLUSION: Gradient pressure therapy effectively reduces symptoms of paclitaxel-induced peripheral neuropathy, improving patients' daily activities. This intervention is recommended for clinical promotion and application.